As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
the contents by NLM or the National Institutes of Health.
Learn more: PMC Disclaimer | PMC Copyright Notice
Learn more: PMC Disclaimer | PMC Copyright Notice
Can J Cardiol. 2007 Feb; 23(2): 159.
PMCID: PMC2650654
Erratum
This corrects the article "Efficacy and tolerability of ezetimibe 10 mg/day coadministered with statins in patients with primary hypercholesterolemia who do not achieve target LDL-C while on statin monotherapy: A Canadian, multicentre, prospective study – the Ezetrol® Add-On Study" in volume 22 on page 1035.
S Bissonnette, R Habib, F Sampalis, S Boukas, JS Sampalis; for the Ezetrol® Add-On Investigators. Efficacy and tolerability of ezetimibe 10 mg/day coad-ministered with statins in patients with primary hypercholesterolemia who do not achieve target LDL-C while on statin monotherapy: A Canadian, multicentre, prospective study – the Ezetrol® Add-On Study. Can J Cardiol 2006;22(12):1035–1044.
Please note that an error was printed in the 10-year coronary artery disease risk row of Table 4, in which the ‘high’ and ‘low’ risk patient groups were reversed. The authors regret the error. The corrected part of the table is as follows:
TABLE 4
Comparison of subjects below and above target low-density lipoprotein cholesterol (LDL-C) levels at six weeks
| Patient group
| ||||
|---|---|---|---|---|
| Below target LDL-C (n=674) | Above target LDL-C (n=163) | P | ||
| 10-year coronary artery disease risk, n (%) | ||||
| High | 623 (92.4) | 154 (94.5) | 0.825‡ | |
| Moderate | 34 (5.0) | 6 (3.7) | ||
| Low | 17 (2.5) | 3 (1.8) | ||
‡P value based on χ2 test
Articles from The Canadian Journal of Cardiology are provided here courtesy of Pulsus Group